Loading stock data…
HYPR
$1.87+0.21 (+12.65%)
Market ClosedLast close May 1
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Hyperfine, Inc. in the Healthcare sector is trading at $1.87. The stock is currently 16% below its 52-week high of $2.22, remaining 54.5% above its 200-day moving average. Technical signals show overbought RSI of 91 and bullish MACD crossover, explaining why HYPR maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 91) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.87
Potential Upside
5%
Whystock Fair Value$1.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$128.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-86.76%
Volume
Today's trading volume
2.12M
Recent News
iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
iRadimed (IRMD) delivered earnings and revenue surprises of +8.89% and +1.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard
A few weeks ago, a research paper out of MIT (the college) crossed my desk that most investors would have ignored.It was about worms. Specifically, it was about a team that had successfully mapped the entire brain of a microscopic worm — every neuron, every connection. Then it laid out what it would take to scale that process from a worm… to a mouse… and eventually, to a human.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now, here’s where things get interesting for us. For deca
Hyperfine receives $40m from Horizon for Swoop System expansion
Hyperfine’s Swoop system has received FDA clearance and offers AI-powered, point-of-care brain imaging for patients of all ages.
Hyperfine (HYPR) Q4 2025 Earnings Call Transcript
Earlier today, Hyperfine Inc. released financial results for the quarter ending December 31, 2025. Before we begin, I'd like to remind that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.
Hyperfine, Inc. Q4 2025 Earnings Call Summary
Moby summary of Hyperfine, Inc.'s Q4 2025 earnings call